Evidence map›Paper›PMID 42555528›Full record

ArticleVirulence2026

Calycosin targets the MAPK-EGR1 signaling axis to inhibit enterovirus 71 replication in cells and human colonic organoids.

Yue Liu, Jiale Wang, Xin Chen, Mengli Wu, Xiangqian Zhang, Yan-Heng Zhou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virulence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yue LiuShaanxi Engineering and Technological Research Center for Conversation and Utilization of Regional Biological Resources, College of Life Sciences, Yan'an University, Yan'an, Shaanxi, China.
Jiale WangShaanxi Engineering and Technological Research Center for Conversation and Utilization of Regional Biological Resources, College of Life Sciences, Yan'an University, Yan'an, Shaanxi, China.
Xin ChenDepartment of Pathogenic Biology, School of Basic Medical Sciences, Gannan Medical University, Ganzhou, Jiangxi, China.ORCID 0000-0002-8980-7032
Mengli WuSchool of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Xiangqian ZhangEngineering Research Center of Microbial Resources Development and Green Recycling, University of Shaanxi Province, Yan'an University, Yan'an, Shaanxi, China.
Yan-Heng ZhouShaanxi Engineering and Technological Research Center for Conversation and Utilization of Regional Biological Resources, College of Life Sciences, Yan'an University, Yan'an, Shaanxi, China.ORCID 0000-0001-7941-8730

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The downstream effectors that mediate the pro‑viral function of the MAPK pathway during enterovirus 71 (EV71) infection remain poorly defined. Here we show that early growth response 1 (EGR1) is independently regulated by each of the three classical MAPK branches including extracellular signal-regulated kinase (ERK), p38 and c-Jun N-terminal kinase (JNK), and serves as a common downstream target of these pathways to promote EV71 replication and virus-induced cell death. Furthermore, we found that the natural isoflavone calycosin (CA) from

Indexed as

Early Growth Response Protein 1Enterovirus A, HumanIsoflavonesMAP Kinase Signaling SystemVirus ReplicationCell LineColonEnterovirus InfectionsHumansOrganoidsSignal Transduction7,3'-dihydroxy-4'-methoxyisoflavoneEarly Growth Response Protein 1EGR1 protein, humanIsoflavonesCalycosincell deathEGR1EV71MAPKorganoidsviral replication

Identifiers

PMID42555528
PMCPMC13449819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.